Abstract
The past three decades have witnessed a radical change in the diagnostic approach to neuroendocrine tumours (NEN). In the early 1990s, Krenning et al. [1] documented the higher diagnostic accuracy of somatostatin receptor scintigraphy (SRS) over conventional morphological procedures (US, CT) for both the detection of the primary tumour and distant metastasis (overall detection rate ranging between 80 and 100 %). In fact the variable presentation of NEN, in terms of both size and primary tumour site, mainly accounts for the lower performance of conventional imaging modalities. The availability of radiotracers specifically binding to somatostatin receptors (SSTR) overexpressed on NEN cells has represented a major advance in the diagnosis of these tumour forms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–31.
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875–82.
Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, Prasad V, Hamm B, Maurer MH. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(1):72–82.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. [68Ga]DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18.
Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S52–60.
Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51(5):669–73.
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10.
Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with [18F]DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7(9):728–34.
Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50(12):1927–32.
Chondrogiannis S, Marzola MC, Al-Nahhas A, Venkatanarayana TD, Mazza A, Opocher G, Rubello D. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun. 2013;34(12):1141–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ambrosini, V., Fanti, S. (2016). PET/CT in Neuroendocrine Tumours. In: Ambrosini, V., Fanti, S. (eds) PET/CT in Neuroendocrine Tumors. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-29203-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-29203-8_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29202-1
Online ISBN: 978-3-319-29203-8
eBook Packages: MedicineMedicine (R0)